Xi-Feng Cui1, Xi-Gang Cui2, Ning Leng1. 1. Department of Nephrology, The Laiyang Central Hospital of Yantai, 111 Changshan Road, Laiyang, Shandong, 265200, P.R. China. 2. Department of Gastrointestinal Surgery, The Yantai Affiliated Hospital of Binzhou Medical University, 717 Jinbu Road, Yantai, Shandong 264200, P.R. China.
Renal cell carcinoma (RCC) is the most common tumor to affect the adult kidney, accounting
for 80–90% of primary malignant renal neoplasms in adults[1]. The pathogenesis of RCC is still unclear, which makes it difficult to
treat. Papillary renal cell carcinoma (PRCC) is the second most common histologic subtype,
accounting for approximately 10% of all renal cell cancers[2]. Papillary tumors are subdivided into type I tumors, which occur
sporadically and metastasize somewhat late, and type II papillary RCC, which is more likely
inherited and has a poorer prognosis[3].
Considering the above, it is necessary to identify therapeutic targets and diagnostic
biomarkers for the treatment of PRCC.The interleukin-20-receptor I complex (IL-20-RI) is composed of two chains, interleukin-20
receptor subunit alpha (IL20RA) and interleukin-20 receptor subunit beta (IL20RB). IL-20-RI
is a receptor for IL-19, IL-20, and IL-24. IL20RB can also form a heterodimer with IL22RA1.
The IL22RA1/IL20RB dimer is a receptor for IL20 and IL24. IL-20R cytokines can be expressed
by both immune cells and epithelial cells and are important for their interaction[4]. IL20RB may affect the IL20 signaling pathway
and may be involved in the pathogenesis of glaucoma[5], vitiligo[6], and
psoriasis[7]. Meanwhile, multiple studies
have also reported that IL20RB carries a big weight in various cancers, for instance
non-small-cell lung cancer (NSCLC)[8],
nasopharyngeal carcinoma (NPC)[9], breast
cancer (BC)[10], and pancreatic ductal
adenocarcinoma (PDAC)[11]. Based on the
above research, IL20RB plays an important role in many cancers, but the function of IL20RB
in PRCC has not been described. The present study was designed to explore its role in PRCC.
Currently, there is no report on IL20RB in PRCC. Therefore, much work remains to be done to
explore the function of IL20RB in PRCC.In the present study, the expression pattern, correlation to clinical characteristics, and
prognostic significance of IL20RB; the capabilities of proliferation, invasion and migration
of PRCC cells; and the underlying mechanism were investigated for the first time, to the
best of our knowledge. Thus, our results provide new insights into possible therapeutic
interventions for further preclinical or clinical studies.
Materials and Methods
Data collection
Data concerning the expression of IL20RB in tumor and normal tissues were downloaded from
The Cancer Genome Atlas (TCGA) database (
https://cancergenome.nih.gov/), including 32
normal cases and 289 tumor cases, and 68 cases with complete clinical data were used to
explore the correlation of IL20RB expression and clinical characteristics (TCGA Project
ID: TCGA-KIRP). The Kaplan-Meier method was used for analysis of the prognostic survival
curve.
Cell culture
We obtained humanPRCC cell lines A498, 786-0, ACHN, and Ketr-3 and normal control cells,
Human Renal Cortical Epithelial (HRCE) cells from the Shanghai cell bank of the Chinese
Academy of Medical Sciences (Shanghai, China). PRCC cells were cultured in RPMI-1640 with
a 10% serum concentration, 100 U/mL penicillin, and 0.1 mg/mL streptomycin (Gibco,
Invitrogen, Carlsbad, CA, USA) at 37°C with 5% CO2 in air. HRCE cells were
cultured in MEM with a 10% serum concentration, 100 U/mL penicillin, and 0.1 mg/mL
streptomycin (Gibco, Invitrogen) under the same conditions. The cells were washed three
times in PBS and then digested with trypsin (Gibco, Invitrogen) when they under the
logarithmic growth stage. When the cells became round, culture medium was added to stop
digestion, the cells were repeatedly blown into single-cell suspension, and they were then
placed into a six-well plate for subsequent experiments.
Transfection
Transfection was performed according to the instructions of Lipofectamine 2000
transfection kits (Invitrogen). The transfection efficiency was detected by western blot
and quantitative real-time PCR (qRT-PCR) 24 h after transfection. The siRNA sequences were
synthesized by GenePharma (Shanghai, China): for si-IL20RB, 5’-GTTCCAAGGAGAAGCCCACA-3’,
forward, 5’-CCGGTC CACATTCTCTGGAA-3’, reverse; for Si-con, 5’-GGAGCG AGATCCCTCCAAAAT-3’,
forward, 5’-GGCTGTTGTCAT ACTTCTCATGG-3’, reverse.
RNA extraction and qRT-PCR
Total RNA was extracted using an RNA extraction kit (Invitrogen). RNA was reverse
transcribed into cDNA with Superscript III reverse transcriptase (Invitrogen), and qRT-PCR
was used to explore the expression of IL20RB. qRT-PCR was executed with 40 circles
consisting of 95°C for 5 min, 95°C for 30 s, 60°C for 45 s, and then 72°C for 30 min. The
primers used were 5’-GTTCCAAGGAGAAGCCCACA-3’, forward, and 5’-CCGGTCCACATTCTCTGGAA-3’,
reverse, for IL20RB and 5’-GGAGCGAGATCCCTCCAAAAT-3’, forward, and
5’-GGCTGTTGTCATACTTCTCATGG-3’, reverse, for GAPDH. Three plates were used for each group,
and experiments were repeated three times independently. The 2−ΔΔCT method was
used to analyze the relative expression of IL20RB.
Western blot
Total protein was extracted from the cells 24 h after transfection with si-IL20RB, and
the concentration was measured by the BCA method. Twenty micrograms of protein from each
sample was subjected to SDS-PAGE and electrotransferred onto PVDF membranes. The membrane
was incubated with 5% skim milk powder for 1 h at room temperature and then incubated with
the primary antibodies, GAPDH (1:1,000, Cell Signaling Technology Inc., Beverly, MA, USA),
IL20RB, E-cadherin, N-cadherin, Vimentin, Snail1, and Snail2 (1:1,000, Abcam, Cambridge,
MA,USA) at 4°C overnight. The membrane was washed with PBS three times and then incubated
with the secondary antibodies (1:1,000, Cell Signaling Technology Inc.) for 1 h at room
temperature. The signal of the protein was visualized by ECL. Quantity One software was
used to measure the relative expression of the protein, and GAPDH was used as the internal
control.
CCK-8 assay
To digest and count the cells 24 h after transfection with siRNA and prepare cell
suspensions, cell suspensions were placed into 96-well plates at a density of 1000
cells/well and cultured at 37°C in a 5% CO2 incubator. Cell activity was
measured by CCK-8 every 24 h, and the cells were incubated at 37°C in the incubator for
1.5 h after adding CCK-8 reagent (Bestbio, Shanghai, China) to each well. A microplate
reader was used to analyze the optical density (OD) at a wavelength of 450 nm and to plot
the proliferation curve.
Transwell
After thawing 100 μL of matrigel overnight, it was added to a 24-well plate in the upper
chamber of a transwell chamber, shaken gently, and placed into a carbon dioxide incubator
for 4-6 h to form a gel. Next, 500 μL serum-free medium was added into the lower chamber
after the culture medium dried, and the substrate membrane was hydrated for half an hour.
Cells were cultured in serum-free culture for 24 h after transfection with siRNA, 100 μL
suspension was then put into the upper chamber at a density of 1×103 cells/μL,
and 500 μL complete culture medium was added into the lower chamber. After overnight
culture, the lower chamber was removed, the cells remaining in the upper chamber were
cleaned, washed with PBS, fixed with 4% paraformaldehyde for 30 min, and stained with 0.1%
crystal violet for 20 min. After cleaning with PBS, 5 visual fields were chosen at random
under a microscope to observe and count.Compared with cell invasion assays, the transwell chamber does not need to be coated with
matrigel in the migration procedure.
Colony-forming assay
Cell exhibiting logarithmic growth were digested with trypsin (Gibco, Invitrogen) and
blown into a single-cell suspension. The cell suspension was prepared at a density of 400
cells per dish and inoculated into a petri dish. It was then cultured at 37°C in a 5%
CO2 incubator for approximately 1–2 weeks. When visible clones appeared in
the petri dish, the culture was terminated. The cells were fixed with 4% paraformaldehyde
and stained with 0.1% crystal violet. Colonies were visualized and subjected to
statistical analysis. The experiment was repeated three times independently.
Statistical analysis
The IBM SPSS22.0 statistical analysis software and GraphPad Prism version 5.0 were used
to analyze the experimental data. The chi-square test was used to analyze the correlation
between genes and clinical characteristics. Survival data were evaluated using univariate
and multivariate Cox proportional hazards models. Student’s test was performed to examine
the difference in two groups. One-way ANOVA analysis with Dunnett’s post hoc test was used
to compare the mean values of multiple samples. P<0.05 was considered
significantly.
Results
Overexpression IL20RB in PRCC patients is related to poor overall survival
Data concerning IL20RB expression in PRCC tissue were extracted from the TCGA database,
and it was revealed that IL20RB was highly expressed in PRCC tissue compared with the
normal tissues (Fig. 1A, P<0.01). We further studied the association of IL20RB expression and clinical
features (Table 1). The data indicated that the expression of IL20RB was related to lymph
nodes (P=0.046) and death (P=0.021) in patients with PRCC. Furthermore, COX regression
analysis suggested that IL20RB may be an independent predictor of prognosis in PRCCpatients (Table
2). In univariate analysis, factors such as IL20RB expression,
stage (I+II/III+IV), and TNM stage were connected with PRCC. In multivariate analysis,
IL20RB expression and pathologic metastasis were correlated with PRCC, suggesting that
IL20RB may be used as an independent predictor of prognosis in patients with PRCC.
Moreover, the overall survival rate of PRCCpatients with high IL20RB expression was lower
than that of patients with low IL20RB expression (Fig.
1B, P<0.01). The results indicated that IL20RB was overexpressed in PRCC
tissues and resulted in a poor prognosis.
Fig. 1.
Interleukin-20 receptor subunit beta (IL20RB) was highly expressed, and its
overexpression in papillary renal cell carcinoma (PRCC) led to a poor prognosis. A:
The expression of IL20RB was higher in tumor tissue than in normal tissue. B: The
overall survival of patients with high expression of IL20RB was decreased compared
with those with low expression.
Table 1.
Relationship Between Interleukin-20 Receptor Subunit Beta (IL20RB) Expression
and Clinicopathologic Features of Patients with Papillary Renal Cell
Carcinoma
Table 2.
Cox Univariate and Multivariate Analysis of Interleukin-20 Receptor Subunit
Beta (IL20RB) in Papillary Renal Cell Carcinoma Patients
Interleukin-20 receptor subunit beta (IL20RB) was highly expressed, and its
overexpression in papillary renal cell carcinoma (PRCC) led to a poor prognosis. A:
The expression of IL20RB was higher in tumor tissue than in normal tissue. B: The
overall survival of patients with high expression of IL20RB was decreased compared
with those with low expression.
IL20RB was highly expressed in the Ketr-3 cell line
To further investigate the role of IL20RB in PRCC, the expression levels of IL20RB in
different PRCC cell lines, including A498, ACHN, 786-0, and Ketr-3, and normal control
HRCE cells were measured by qPCR. The data showed that IL20RB was highly expressed in PRCC
cell lines, especially in Ketr-3, compared with the normal control HRCE cells (Fig. 2, P<0.01). Thus, in the following experiment, Ketr-3 cells were used to explore
the biological function of IL20RB in PRCC. The experimental results in vitro were
consistent with the results of analysis at the tissue level, indicating that IL20RB was
highly expressed in PRCC.
Fig. 2.
The overexpression of interleukin-20 receptor subunit beta (IL20RB) in papillary
renal cell carcinoma (PRCC) cell lines. The expression levels of IL20RB in different
cell lines, including A498, ACHN, 786-0, Ketr-3, and human renal cortical epithelial
(HRCE) cells, were analyzed by quantitative real-time PCR (qRT-PCR). *P<0.05;
**P<0.01.
The overexpression of interleukin-20 receptor subunit beta (IL20RB) in papillary
renal cell carcinoma (PRCC) cell lines. The expression levels of IL20RB in different
cell lines, including A498, ACHN, 786-0, Ketr-3, and human renal cortical epithelial
(HRCE) cells, were analyzed by quantitative real-time PCR (qRT-PCR). *P<0.05;
**P<0.01.
Proliferation of PRCC cells was significantly reduced after knockdown of
IL20RB
Next, based on the importance of IL20RB in PRCC and the discovery that IL20RB was
overexpressed in PRCC and resulted in a poor prognosis, we investigated IL20RB effects on
PRCC cells. We began by silencing IL20RB using siRNA technology in Ketr-3 cells. Obvious
reductions in both mRNA and protein levels were observed (Fig. 3A, P<0.01, Fig. 3B and 3C, P<0.05).
Then, in order to observe the functions of IL20RB in terms of PRCC cell characteristics
after knockdown of IL20RB, we used CCK-8 and colony formation methods to investigate the
proliferation activity of Ketr-3 cells. The results showed that the OD value in Ketr-3
cells was remarkably decreased after knockdown for 48 h and 72 h (Fig. 3D, P<0.01). Furthermore, the colony formation efficiency
of Ketr-3 cells treated with si-IL20RB was measured. The number of colonies formed was
obviously decreased compared with the control group (Fig. 3E and 3F, P<0.01). These results demonstrated that IL20RB silencing can
reduce the proliferation of PRCC cells.
Fig. 3.
Knockdown of interleukin-20 receptor subunit beta (IL20RB) by small interfering
RNA (siRNA) reduced the proliferation of Ketr-3 cells. A: Detection of interference
efficiency by quantitative real-time PCR (qRT-PCR) after knockdown of IL20RB.
**P<0.01. B: The protein levels of IL20RB were decreased. C: Quantification of
the protein levels of IL20RB. *P<0.05. D: The results of CCK-8 indicated that
knockdown of IL20RB restrained Ketr-3 cell proliferation. **P<0.01. E: The number
of colonies formed was decreased. F: Quantification of the number of colonies
formed. **P<0.01.
Knockdown of interleukin-20 receptor subunit beta (IL20RB) by small interfering
RNA (siRNA) reduced the proliferation of Ketr-3 cells. A: Detection of interference
efficiency by quantitative real-time PCR (qRT-PCR) after knockdown of IL20RB.
**P<0.01. B: The protein levels of IL20RB were decreased. C: Quantification of
the protein levels of IL20RB. *P<0.05. D: The results of CCK-8 indicated that
knockdown of IL20RB restrained Ketr-3 cell proliferation. **P<0.01. E: The number
of colonies formed was decreased. F: Quantification of the number of colonies
formed. **P<0.01.
Silencing of IL20RB reduced Ketr-3 cells migration and invasion
Subsequently, a transwell assay was used to measure migration and invasion abilities in
Ketr-3 cells after knockdown of IL20RB. The number of invading Ketr-3 cells was obviously
reduced compared with the control group (Fig. 4A and
4B, P<0.01), indicating that their invasion ability was obviously inhibited after
infection with si-IL20RB. Meanwhile, the number of migrating Ketr-3 was relatively
decreased compared with the control group (Fig. 4A and
4B). The data indicated that knockdown of IL20RB impaired the invasion and
migration abilities of PRCC cells.
Fig. 4.
A transwell assay was used to assess the effect of interleukin-20 receptor subunit
beta (IL20RB) on cell invasion and migration. A: Compared with the Si-con group,
invasion and migration of Ketr-3 cells were decreased. B: Quantification of invasion
and migration of Ketr-3 cells. **P<0.01.
A transwell assay was used to assess the effect of interleukin-20 receptor subunit
beta (IL20RB) on cell invasion and migration. A: Compared with the Si-con group,
invasion and migration of Ketr-3 cells were decreased. B: Quantification of invasion
and migration of Ketr-3 cells. **P<0.01.
Knockdown of IL20RB affected epithelial-mesenchymal transition in Ketr-3
cells
Epithelial-mesenchymal transition (EMT) is recognized to be a process in which epithelial
cells transdifferentiate into motile mesenchymal cells, and it contributes pathologically
to fibrosis and cancer progression[12].
Hallmarks of EMT include the loss of expression or function of E-cadherin, reduced
abundance of tight junction proteins, and high expression of N-cadherin, Snail1, Snail2,
and Vimentin[13]. In our study, we found
that after knockdown of IL20RB in Ketr-3 cells, the expression of E-cadherin was obviously
increased; however, the N-cadherin, Snail1, Snail2, and Vimentin were reduced by varying
degrees compared with the control group (Fig. 5A and
5B, P<0.05). The findings indicated that IL20RB may function via the EMT to
influence the invasion and migration of PRCC cells.
Fig. 5.
Silencing of interleukin-20 receptor subunit beta (IL20RB) affected the
epithelial-mesenchymal transition (EMT) in papillary renal cell carcinoma (PRCC)
cells. A: Western blot was performed to evaluate the expression of EMT-related
proteins including E-cadherin, N-cadherin, Snail1, Snail2, and Vimentin. B:
Quantification of the expression levels of EMT-related proteins, *P<0.05.
Silencing of interleukin-20 receptor subunit beta (IL20RB) affected the
epithelial-mesenchymal transition (EMT) in papillary renal cell carcinoma (PRCC)
cells. A: Western blot was performed to evaluate the expression of EMT-related
proteins including E-cadherin, N-cadherin, Snail1, Snail2, and Vimentin. B:
Quantification of the expression levels of EMT-related proteins, *P<0.05.
Discussion
Renal cell carcinoma, which accounts for 90% of renal malignancies, is the most lethal
tumor of the urinary system[14]. In 2004,
the World Health Organization classification of adult renal tumors stratified renal cell
carcinoma into several subtypes, of which clear cell, papillary, and chromophobe tumors
accounted for 70%, 10–15% and 5% of the tumors, respectively[15]. Different types of RCC have different biological functions,
prognoses, and treatment options. PRCC, as the second largest type of RCC, is difficult to
diagnose and has a poor prognosis and limited therapeutic options[16]. Therefore, surgical treatment is the first choice, and
interferon and interleukin-2 are the main immunotherapy methods at present. For metastatic
RCC, targeted therapy is becoming the standard adjuvant therapy to improve overall survival.
Thus, it is extremely important to discover the target genes to cure PRCC.The IL-20 subfamily is involved both in amplified inflammatory responses, particularly
during autoimmunity and chronic inflammation, and in anti-inflammatory responses, such as
tissue protection and regeneration. This subfamily includes the cytokines IL-19, IL-20,
IL-22, IL-24, and IL-26 and the receptors IL-20RA, IL-20RB, IL-10RB, and IL-22RA1[17]. Different ligands have unique biological
activities; for instance, IL-19 has been reported to directly affect immune cells[18], IL-20 has shown activity on skin
biology[19], and IL24 plays a role in
promoting apoptosis in tumors[20]. IL20RB,
as an IL20 subfamily receptor, can be combined with these ligands to perform a variety of
functions, such as activation of the Janus kinase (JAK)-signal transducer and activator of
transcription (STAT) pathway (JAK-STAT)[21]
and stimulation of stable proliferation of BaF3 cells. However, the function of IL20R in
PRCC has not yet been reported. Hence, we analyzed the expression of IL20RA and IL20RB in
PRCC data from the TCGA database. The data showed no significant difference in the
expression level of IL20RA in PRCC tissues; however, the abnormal expression of IL20RB in
PRCC tissues and the characteristics significantly related to prognosis led us to focus of
IL20RB. To the best of our knowledge, this is the first report on the expression and
prognosis of IL20RB in PRCC, as well as the effect on the proliferation, invasion, and
migration of PRCC cells after knockdown of IL20RB. IL20RB expression is related to the poor
prognosis of patients with PRCC, suggesting that IL20RB, as a tumor-promoting gene, may have
a positive regulatory role in PRCC. The findings of the present study showed that IL20RB has
a positive effect on the proliferation, invasion, and migration abilities of PRCC cells and
that silencing of IL20RB had an effect on the expression of EMT pathway-related proteins.
Therefore, we hypothesized that IL20RB regulated the occurrence of PRCC through the EMT
pathway, but the specific mechanism remains unclear.The epithelial-mesenchymal transition is a key regulator of metastasis through promotion of
tumor cell invasion and metastasis to distant organs[22]. Recent studies have reported that the EMT plays vital role in the
occurrence and development of various tumors, including RCC[23]. During the EMT, E-cadherin is one of the strongest markers
for cancer diagnosis and progression routinely used in the clinic[24]. Furthermore, abnormal expression of Snail was related to poor
survival in breast[25],
hepatocellular[26], and
ovarian[27] cancers. The overexpression
of Vimentin in cancer and its relationship with growth and metastasis suggested that it may
be an indicator of poor prognosis in many cancers[28]. In the present study, we detected the key proteins, including
E-cadherin, N-cadherin, Snail1, Snail2, and Vimentin in the EMT pathway after knockdown of
IL20RB. Compared with the control, the expression of E-cadherin was obviously upregulated,
while the other proteins exhibiting positive correlation, including N-cadherin, Snail1,
Snail2, and Vimentin, were significantly downregulated. The results showed that silencing of
IL20RB limited the invasion and migration of PRCC cells probably through the EMT. However,
the detailed molecular mechanism has not been well defined, and this will require further
research.Overall, all the data in the present study demonstrated that IL20RB was highly expressed in
both PRCC tissues and cells and that overexpression of IL20RB in PRCC led to poor overall
survival. Based on the findings of the knockdown experiment, IL20RB repressed the
proliferation, invasion, and migration capacities of PRCC cells by regulating the EMT
pathway. Therefore, we surmised that IL20RB exists as a key molecule in the occurrence and
development of PRCC. We predicted that IL20RB could possibly be used for diagnosis of PRCC
and a novel targeted therapy.
Authors: Chaan S Ng; Christopher G Wood; Paul M Silverman; Nizar M Tannir; Pheroze Tamboli; Carl M Sandler Journal: AJR Am J Roentgenol Date: 2008-10 Impact factor: 3.959
Authors: H Blumberg; D Conklin; W F Xu; A Grossmann; T Brender; S Carollo; M Eagan; D Foster; B A Haldeman; A Hammond; H Haugen; L Jelinek; J D Kelly; K Madden; M F Maurer; J Parrish-Novak; D Prunkard; S Sexson; C Sprecher; K Waggie; J West; T E Whitmore; L Yao; M K Kuechle; B A Dale; Y A Chandrasekher Journal: Cell Date: 2001-01-12 Impact factor: 41.582
Authors: Syed Haider; Jun Wang; Ai Nagano; Ami Desai; Prabhu Arumugam; Laurent Dumartin; Jude Fitzgibbon; Thorsten Hagemann; John F Marshall; Hemant M Kocher; Tatjana Crnogorac-Jurcevic; Aldo Scarpa; Nicholas R Lemoine; Claude Chelala Journal: Genome Med Date: 2014-12-03 Impact factor: 11.117
Authors: Ruhina S Laskar; Peng Li; Szilvia Ecsedi; Behnoush Abedi-Ardekani; Geoffroy Durand; Nivonirina Robinot; Jean-Noël Hubert; Vladimir Janout; David Zaridze; Anush Mukeria; Dana Mates; Ivana Holcatova; Lenka Foretova; Beata Swiatkowska; Zoran Dzamic; Sasa Milosavljevic; Robert Olaso; Anne Boland; Jean-François Deleuze; David C Muller; James D McKay; Paul Brennan; Florence Le Calvez-Kelm; Ghislaine Scelo; Estelle Chanudet Journal: Hum Mol Genet Date: 2021-04-27 Impact factor: 6.150